6 Nephrology Headlines You Missed in July 2025

Nephrology in September 2026: FDA approves finerenone for CKD in T1D and obinutuzumab for nephrotic syndrome, plus ORIGIN 3 IgAN data.

Nephrology in Q3 2026: FDA approvals for atacicept, iptacopan, finerenone, and obinutuzumab, plus 2-year IgAN data and CKD screening.

In this session, Cheri Frey, MD, shared a framework for evaluating skincare products, from ingredient plausibility to clinically meaningful results.

Andrea Murina, MD, reviewed strategies for optimizing HS biologics, combining therapies, and reconsidering the role of surgery.

HCPLive previews Fall Clinical 2026 in Las Vegas, October 8-11, with key sessions on atopic dermatitis, psoriasis, and vitiligo, plus expert interviews.

With the Viaskin Peanut BLA filed for ages 4 to 7, here's where the patch, omalizumab, and office OIT fit for peanut allergy.With the Viaskin Peanut BLA filed for ages 4 to 7, here's where the patch, omalizumab, and office OIT fit for peanut allergy.

The guideline chair answers key questions on new ferritin cutoffs, symptoms without anemia, inflammation, and lab reporting.

Patients with obesity or overweight and T2D saw substantially greater mean weight loss and HbA1c improvement with petrelintide versus placebo.